Gastrointestinal Stromal Tumor (GIST) News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Activity of PD-1 Inhibitor Limited in Soft-Tissue Sarcomas
Treatment with the PD-1 inhibitor pembrolizumab plus metronomic cyclophosphamide had limited activity in patients with soft-tissue sarcomas and gastrointestinal stromal tumors. (Source: CancerNetwork)
Source: CancerNetwork - July 11, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Sarcoma Source Type: news
KIT Mutations Linked to Imatinib Response in GIST KIT Mutations Linked to Imatinib Response in GIST
Different KIT mutations have various associations with the response of gastrointestinal stromal tumors (GISTs) to adjuvant imatinib, according to results from a Scandinavian Sarcoma Group multicenter trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news
Immunicum begins enrolment in Phase I/II trial of INTUVAX to treat GIST
Swedish-based biopharmaceutical company Immunicum has commenced enrolment in the Phase I/II clinical trial of INTUVAX for the treatment of patients with gastrointestinal stromal tumour (GIST). (Source: Drug Development Technology)
Source: Drug Development Technology - March 8, 2017 Category: Pharmaceuticals Source Type: news
Imatinib of Long-Term Help in Some Patients With GI Stromal Tumors Imatinib of Long-Term Help in Some Patients With GI Stromal Tumors
A substantial minority of patients with advanced gastrointestinal stromal tumors (GIST) treated with imatinib mesylate show long-term survival, according to a trial analysis presenting new molecular data.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 21, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Study shows strong long-term survival rates for patients with GIST
Nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years, a new report outlines. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 20, 2017 Category: Science Source Type: news
SWOG study shows strong long-term survival rates for patients with GIST
(SWOG) Researchers show that nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years. Results are published in JAMA Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2017 Category: Global & Universal Source Type: news
Clinical Insights Into Gastrointestinal Stromal Tumours Clinical Insights Into Gastrointestinal Stromal Tumours
This study examined the treatment outcomes of GISTs, highlighting some of the diagnostic and therapeutic challenges.Frontline Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2017 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news
Surgery May Be Preferable in Young Adults With GI Stromal Tumors Surgery May Be Preferable in Young Adults With GI Stromal Tumors
Young adults with gastrointestinal stromal tumors (GISTs) appear to fare best after undergoing operative treatment, according to a retrospective study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 26, 2017 Category: Surgery Tags: General Surgery News Source Type: news
Small intestine GIST associated with better prognosis in younger patients
Gastrointestinal stromal tumors (GIST) are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. Researchers report findings from the first population-based analysis of AYA patients with GIST. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 18, 2017 Category: Science Source Type: news
Small intestine GIST associated with better prognosis in younger patients
(University of California - San Diego) Gastrointestinal stromal tumors (GIST) are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. Researchers at the University of California San Diego School of Medicine report findings from the first population-based analysis of AYA patients with GIST. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 18, 2017 Category: Global & Universal Source Type: news
Columbia, NewYork-Presbyterian and non-profit Life Raft Group form cancer partnership
(Columbia University Medical Center) Collaboration will investigate the efficacy of a system biology approach to identifying treatment options for patients with advanced gastrointestinal stromal tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2017 Category: Global & Universal Source Type: news
New gene fusions, mutations linked to gastrointestinal stromal tumors
In recent years, researchers have identified specific gene mutations linked to gastrointestinal stromal tumors (GIST), which primarily occur in the stomach or small intestine, but 10 to 15 percent of adult GIST cases and most pediatric cases lack the tell-tale mutations, making identification and treatment difficult. Researchers have identified new gene fusions and mutations associated with this subset of GIST patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 15, 2016 Category: Science Source Type: news
New gene fusions and mutations linked to gastrointestinal stromal tumors
(University of California - San Diego) In recent years, researchers have identified specific gene mutations linked to gastrointestinal stromal tumors (GIST), which primarily occur in the stomach or small intestine, but 10 to 15 percent of adult GIST cases and most pediatric cases lack the tell-tale mutations, making identification and treatment difficult. Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified new gene fusions and mutations associated with this subset of GIST patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 15, 2016 Category: Cancer & Oncology Source Type: news
Regorafenib from Bayer submitted to health authorities seeking approval in second-line treatment of liver cancer
Bayer has announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor regorafenib in the U.S., Japan and Europe, for the second line treatment of patients with unresectable hepatocellular carcinoma (HCC). Regorafenib is already approved under the brand name Stivarga® in many countries to treat metastatic colorectal cancer and metastatic gastrointestinal stromal tumors. (Source: World Pharma News)
Source: World Pharma News - November 9, 2016 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Researchers identify new drug target for gastrointestinal stromal tumors
(University of California - San Diego) Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 1, 2016 Category: Global & Universal Source Type: news
